AMRI initiated a Phase I study of ALB109564(a), a tubulin inhibitor designed to kill cancer cells by preventing cell mitosis. The study will be conducted at four trial sites for a period of nine to 12 months and will include as many as 40 subjects. The drug will be administered intravenously to cancer patients with advanced solid tumors in an ascending dose study to evaluate safety, tolerability and pharmacokinetic profile of the drug.     In preclinical testing, the compound has been shown...